Line of Credit 
Print FormatBRIEF-Nurix Therapeutics Reports Dosing Of First Patient In Phase 1 Clinical Trial Of Nx-5948 In Development For B-Cell Leukemias And Lymphomas
* NURIX THERAPEUTICS REPORTS DOSING OF FIRST PATIENT IN PHASE 1 CLINICAL TRIAL OF NX-5948, A SELECTIVE BTK DEGRADER, IN DEVELOPMENT FOR B-CELL LEUKEMIAS AND LYMPHOMAS
* NURIX THERAPEUTICS INC (NRIX) - TRIAL IS DESIGNED TO EVALUATE SAFETY AND TOLERABILITY OF NX-5948 IN ADULTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES
* NURIX THERAPEUTICS (NRIX) - EXPECTS TO HAVE INITIAL SAFETY AND PHARMACOKINETIC AND PHARMACODYNAMIC DATA FROM PHASE 1A PORTION OF STUDY IN SECOND HALF OF 2022 Source text for Eikon: Further company coverage:
